Ranimustine - Docslib

Sign Up
Log In
Upload

Sign Up
Log In
Upload

Home
» Tags
» Ranimustine

Ranimustine

Tanibirumab (CUI C3490677) Add to Cart
Cancers
Oligodendroglial Tumor Chemotherapy Using “Decreased-Dose- Intensity”
Ep 2569287 B1
(12) Patent Application Publication (10) Pub. No.: US 2017/0224667 A1 AZUMA Et Al
Multistage Delivery of Active Agents
WO 2017/074211 Al 4 May 20 17 (04.05.2017) W P O P C T
Efficacy and Feasibility of Procarbazine, Ranimustine and Vincristine Chemotherapy, and the Role of Surgical Resection in Anaplastic Oligodendroglioma
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
5-Aminolevulinic Acid-Mediated Photodynamic Therapy Can Target Aggressive Adult T Cell Leukemia/Lymphoma Resistant to Convention
Proficient Human Colorectal Cancer Cells
Human Leukocyte Antigen Class II Expression Is a Good Prognostic Factor in Adult T-Cell Leukemia/Lymphoma
E-Table 1. Drug Classification Category Name Generic Name
New Consecutive High-Dose Chemotherapy Modality with Fractionated Blood Stem Cell Support in the Treatment of High-Risk Pediatric Solid Tumors: a Feasibility Study
Ehealth DSI [Ehdsi V2.2.1] European Commission
Ep 3067054 A1
Antigen Binding Protein and Its Use As Addressing Product for the Treatment of Cancer
CASE REPORT Intravenous Busulfan-Based Conditioning With

Top View

Stembook 2018.Pdf
Case Report Fatal Veno-Occlusive Disease (VOD)
Development of Newly Synthesized Chromone Derivatives with High Tumor Speciﬁcity Against Human Oral Squamous Cell Carcinoma
Promising Survival for Patients with Glioblastoma Multiforme Treated with Individualised Chemotherapy Based on in Vitro Drug Sensitivity Testing
Printable Version [PDF]
Orbital MALT Lymphoma After Autologous Stem Cell Transplantation for Follicular Lymphoma As Relapse of Diffuse Large B-Cell Lymphoma
(12) United States Patent (1O) Patent No.: US 8,173,115 B2 Decuzzi Et Al
(NCCN Guidelines®) T-Cell Lymphomas
Optimizing Management of Patients with Adult T Cell Leukemia-Lymphoma
Aggressive Non-Hodgkin Lymphoma
Viral Oncology: Molecular Biology and Pathogenesis
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
(12) Patent Application Publication (10) Pub. No.: US 2016/0220537 A1 GARNER Et Al
Proposal for the Inclusion of Mesna (Sodium 2-Mercaptoethane Sulfonate)
United States Patent $835 a 88: As: Inhibitor 1-((R)-3-(4-Amino-3-(4
Revisiting Intrathecal Therapy in Infants and Children Sharon Conroy, Martin Garnett, Michael Vloeberghs, Richard Grundy, Ian Craven, David Walker
United States Patent (10) Patent No.: US 8,173,177 B2 Dao Et Al
MCVAC) Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation for High-Risk Diffuse Large B-Cell Lymphoma

© 2024 Docslib.org Feedback